Treatment Outcome Data
cancer, deaths, death, failure
EVENTS, METASTASIS, CANCER
Median (IQR) follow-up for surviving patients was 9.0 (7.7-9.3) years compared with 2.5 (2.1-2.9) years for the initial report. After the initial report, 7 additional deaths were reported, for a total of 13 deaths (29.5%). Estimated 5- and 7-year OS rates were 79.5% (95% CI, 67.6%-91.5%) and 69.7% (95% CI, 55.9%-83.5%), respectively. After the initial report, 7 additional PFS events were reported, for a total of 19 events (43.2%; 6 patients with locoregional progression [13.6%], 8 patients with distant progression [18.2%], and 5 patients who died without progression [11.4%]). The first failure among new events was locoregional progression in 2 patients, distant metastasis in 3 patients, death due to other causes in 1 patient, and death due to unknown causes in 1 patient. Estimated 5- and 7-year PFS rates were 61.2% (95% CI, 46.8%-75.6%) and 56.3% (95% CI, 41.5%-71.1%), respectively. After the initial report, 5 additional LRPF events (4 locoregional progressions and 1 death due to unknown causes) were reported, for a total of 12 events (27.3%; 8 locoregional progressions, 2 deaths due to study cancer, and 2 deaths due to unknown causes). Estimated 5- and 7-year LRPF interval rates were 74.9% (95% CI, 61.4%-86.6%) and 72.3% (95% CI, 58.4%-84.7%), respectively. After the initial report, 4 additional DMF events were reported, for a total of 9 events (20.5%). Estimated 5- and 7-year DMF interval rates were both 79.5% (95% CI, 66.4%-90.0%). Estimated 5- and 7-year DMF survival rates were 65.8% (95% CI, 51.8%-79.9%) and 60.9% (95% CI, 46.4%-75.5%). 